Publication Delay of Randomized Trials on 2009 Influenza A (H1N1) Vaccination

Ioannidis, John P. A.; Manzoli, Lamberto; De Vito, Corrado; D'Addario, Maddalena; Villari, Paolo
December 2011
PLoS Clinical Trials;Dec2011, Vol. 6 Issue 12, p1
Academic Journal
Background: Randomized evidence for vaccine immunogenicity and safety is urgently needed in the setting of pandemics with new emerging infectious agents. We carried out an observational survey to evaluate how many randomized controlled trials testing 2009 H1N1 vaccines were published among those registered, and what was the time lag from their start to publication and from their completion to publication. Methods: PubMed, EMBASE and 9 clinical trial registries were searched for eligible randomized controlled trials. The units of the analysis were single randomized trials on any individual receiving influenza vaccines in any setting. Results: 73 eligible trials were identified that had been registered in 2009–2010. By June 30, 2011 only 21 (29%) of these trials had been published, representing 38% of the randomized sample size (19905 of 52765). Trials starting later were published less rapidly (hazard ratio 0.42 per month; 95% Confidence Interval: 0.27 to 0.64; p<0.001). Similarly, trials completed later were published less rapidly (hazard ratio 0.43 per month; 95% CI: 0.27 to 0.67; p<0.001). Randomized controlled trials were completed promptly (median, 5 months from start to completion), but only a minority were subsequently published. Conclusions: Most registered randomized trials on vaccines for the H1N1 pandemic are not published in the peer-reviewed literature.


Related Articles

  • Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine. Pauksens, Karlis // Infection Ecology & Epidemiology;2013, Vol. 3, p1 

    Introduction: In Sweden in 2009, two doses of the pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine were recommended for those with HIV infection along with one dose of seasonal trivalent influenza vaccine (TIV). At that time, no data for HIV patients and their response to the...

  • Immunogenicity of a half-dose of adjuvanted 2009 pandemic H1N1 influenza vaccine in adults: a prospective cohort study. Coleman, B.; Kuster, S.; Gubbay, J.; Scheifele, D.; Li, Y.; Low, D.; Crowcroft, N.; Mazzulli, T.; Shi, L.; Halperin, S.; Law, B.; McGeer, A. // European Journal of Clinical Microbiology & Infectious Diseases;Apr2012, Vol. 31 Issue 4, p591 

    We aimed to assess the immunogenicity of a single half-dose of AS03-adjuvanted monovalent 2009 pandemic H1N1 vaccine in healthy adults. Healthy subjects age 20-60 years were prospectively enrolled in a cohort receiving intramuscular administration of a single half-dose (1.875 μg of...

  • H1N1 vaccine was safe and effective in young children.  // Infectious Diseases in Children;Dec2010, Vol. 23 Issue 12, p35 

    The article focuses on a study which examined the safety and effectiveness of novel influenza A H1N1 vaccine in young children.

  • 2009 H1N1 Vaccination in Minnesota. MUSCOPLAT, MIRIAM HALSTEAD; RODDY, MARGARET; PARILLA, ELIZABETH; DAVEY, CYNTHIA S.; FLEEGE, LAURA; WHITE, KAREN; EHRESMANN, KRISTEN // Minnesota Medicine;Sep2013, Vol. 96 Issue 9, p49 

    According to Minnesota Immunization Information Connection (MIIC) data, 23% of Minnesotans were vaccinated against 2009 pandemic H1N1 influenza. We analyzed 2009 H1N1 vaccination data at the ZIP code level to learn more about who received the vaccine between 2009 and 2010. We found significant...

  • Asymptomatic ratio for seasonal H1N1 influenza infection among schoolchildren in Taiwan. Ying-Hen Hsieh; Chen-An Tsai; Chien-Yu Lin; Jin-Hua Chen; Chwan-Chuen King; Day-Yu Chao; Kuang-Fu Cheng // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background Studies indicate that asymptomatic infections do indeed occur frequently for both seasonal and pandemic influenza, accounting for about one-third of influenza infections. Studies carried out during the 2009 pH1N1 pandemic have found significant antibody response against seasonal H1N1...

  • Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons. Jackson, Lisa A.; Chen, Wilbur H.; Stapleton, Jack T.; Dekker, Cornelia L.; Wald, Anna; Brady, Rebecca C.; Edupuganti, Srilatha; Winokur, Patricia; Mulligan, Mark J.; Keyserling, Harry L.; Kotloff, Karen L.; Rouphael, Nadine; Noah, Diana L.; Hill, Heather; Wolff, Mark C. // Journal of Infectious Diseases;Sep2012, Vol. 206 Issue 6, p811 

    Background. Adjuvanted vaccines have the potential to improve influenza pandemic response. AS03 adjuvant has been shown to enhance the immune response to inactivated influenza vaccines.Methods. This trial was designed to evaluate the immunogenicity and safety of an inactivated 2009 H1N1...

  • A novel sequence-based antigenic distance measure for H1N1, with application to vaccine effectiveness and the selection of vaccine strains. Pan, Keyao; Subieta, Krystina C.; Deem, Michael W. // PEDS: Protein Engineering, Design & Selection;Mar2011, Vol. 24 Issue 3, p291 

    H1N1 influenza causes substantial seasonal illness and was the subtype of the 2009 influenza pandemic. Precise measures of antigenic distance between the vaccine and circulating virus strains help researchers design influenza vaccines with high vaccine effectiveness. We here introduce a...

  • Pandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome. Verity, C.; Stellitano, L.; Winstone, A. M.; Stowe, J.; Andrews, N.; Miller, E. // Archives of Disease in Childhood;Jun2014, Vol. 99 Issue 6, p532 

    Objective: To record clinical findings in all new cases of Guillain-Barré syndrome (GBS) or Fisher syndrome (FS) in UK children in the 2 years following September 2009 and determine the proportion temporally associated with recent infections, pandemic H1N1 (2009) strain influenza vaccination...

  • IN THE NEWS: DO WE NEED FLU SHOTS? J. P. // Baby Talk;Aug2010, Vol. 75 Issue 6, p48 

    The article presents the release of the universal recommendation from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices for adults on H1N1 flu virus, which means that the whole U.S. population are boosted to get vaccinated.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics